Lomustine
Back to searchMolecule Structure
Scientific Name
Lomustine
Description of the Drug
Lomustine is an alkylating agent used as a part of chemotherapeutic regimens for the treatment of primary and metastatic brain tumors as well as refractory or relapsed Hodgkin’s disease in addition to surgical and/or radiotherapeutic treatments.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01206
http://www.drugbank.ca/drugs/DB01206
Brand Name(s)
Ccnu, Ceenu, Gleostine
Company Owner(s)
Corden Pharma Latina Spa
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
Atlas | lomustine | |
SureChEMBL | SCHEMBL3995 | |
PharmGKB | PA164749407 | |
Human Metabolome Database | HMDB0015337 | |
DrugBank | DB01206 | |
PubChem: Thomson Pharma | 15121730 | |
PubChem | 3950 | |
Nikkaji | J3.122D | |
BindingDB | 50247919 | |
EPA CompTox Dashboard | DTXSID2023222 | |
DrugCentral | 1596 | |
ChemicalBook | CB5123021 | |
Guide to Pharmacology | 7214 | |
rxnorm | LOMUSTINE | GLEOSTINE |
KEGG Ligand | C07079 | |
ChEBI | 6520 | |
ZINC | ZINC000003831006 |